JP2014087372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014087372A5 JP2014087372A5 JP2014017760A JP2014017760A JP2014087372A5 JP 2014087372 A5 JP2014087372 A5 JP 2014087372A5 JP 2014017760 A JP2014017760 A JP 2014017760A JP 2014017760 A JP2014017760 A JP 2014017760A JP 2014087372 A5 JP2014087372 A5 JP 2014087372A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- long
- memory
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 231100000331 toxic Toxicity 0.000 claims 3
- 230000002588 toxic effect Effects 0.000 claims 3
- 102000001398 Granzyme Human genes 0.000 claims 2
- 108060005986 Granzyme Proteins 0.000 claims 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 2
- 102100033467 L-selectin Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101150017888 Bcl2 gene Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 108091008915 immune receptors Proteins 0.000 claims 1
- 102000027596 immune receptors Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 231100000863 loss of memory Toxicity 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 231100000183 lymphotoxic Toxicity 0.000 claims 1
- 230000001917 lymphotoxic effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
- 229930192851 perforin Natural products 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2424108P | 2008-01-29 | 2008-01-29 | |
| US61/024,241 | 2008-01-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010545015A Division JP2011510653A (ja) | 2008-01-29 | 2009-01-28 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015222014A Division JP2016027828A (ja) | 2008-01-29 | 2015-11-12 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
| JP2017178253A Division JP6665141B2 (ja) | 2008-01-29 | 2017-09-15 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014087372A JP2014087372A (ja) | 2014-05-15 |
| JP2014087372A5 true JP2014087372A5 (enExample) | 2015-03-26 |
| JP6324092B2 JP6324092B2 (ja) | 2018-05-16 |
Family
ID=40913463
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010545015A Pending JP2011510653A (ja) | 2008-01-29 | 2009-01-28 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
| JP2014017760A Active JP6324092B2 (ja) | 2008-01-29 | 2014-01-31 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
| JP2015222014A Pending JP2016027828A (ja) | 2008-01-29 | 2015-11-12 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
| JP2017178253A Active JP6665141B2 (ja) | 2008-01-29 | 2017-09-15 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
| JP2018232409A Pending JP2019041772A (ja) | 2008-01-29 | 2018-12-12 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010545015A Pending JP2011510653A (ja) | 2008-01-29 | 2009-01-28 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015222014A Pending JP2016027828A (ja) | 2008-01-29 | 2015-11-12 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
| JP2017178253A Active JP6665141B2 (ja) | 2008-01-29 | 2017-09-15 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
| JP2018232409A Pending JP2019041772A (ja) | 2008-01-29 | 2018-12-12 | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9090875B2 (enExample) |
| EP (2) | EP2245142B1 (enExample) |
| JP (5) | JP2011510653A (enExample) |
| CA (1) | CA2713462C (enExample) |
| ES (2) | ES2666667T3 (enExample) |
| WO (1) | WO2009097119A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009097119A2 (en) * | 2008-01-29 | 2009-08-06 | Fred Hutchinson Cancer Research Center | Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity |
| WO2012015662A1 (en) * | 2010-07-27 | 2012-02-02 | Baylor Research Institute | Il-18 receptor as a novel target of regulatory t cells in cancer |
| WO2013066485A2 (en) * | 2011-08-31 | 2013-05-10 | Asea Alexzander A | Compositions and methods for treatment of metastatic cancer |
| AU2013224027B2 (en) | 2012-02-23 | 2019-01-24 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| PH12019550223A1 (en) | 2012-08-20 | 2024-02-19 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| WO2014039044A1 (en) | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
| US9844569B2 (en) | 2013-03-01 | 2017-12-19 | The United State Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor reactive T cells from peripheral blood |
| JP6696969B2 (ja) | 2014-04-16 | 2020-05-20 | ユノ・セラピューティクス・ゲーエムベーハーＪｕｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｇｍｂｈ | 細胞の集団を拡大する方法、キット、及び装置 |
| SG11201608862SA (en) | 2014-04-23 | 2016-11-29 | Juno Therapeutics Inc | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| CN105754938A (zh) * | 2014-12-17 | 2016-07-13 | 四川新生命干细胞科技股份有限公司 | 一种从脐带血中分离单个核细胞的试剂盒及方法 |
| CN108348550A (zh) * | 2015-07-21 | 2018-07-31 | 希望之城公司 | 用于表达嵌合抗原受体和其它受体的t细胞 |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| KR20180108567A (ko) | 2015-10-22 | 2018-10-04 | 주노 테라퓨틱스 게엠베하 | 형질도입을 위한 방법, 키트, 제제 및 장치 |
| CA3040533A1 (en) * | 2016-12-02 | 2018-06-07 | Cartesian Therapeutics, Inc. | Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells |
| WO2019094983A1 (en) * | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| BR112020023336A2 (pt) * | 2018-05-15 | 2021-03-16 | Case Western Reserve University | Receptor de antígeno quimérico de longa vida (car) que expressa células t para terapia de câncer |
| CN120605327A (zh) * | 2019-11-06 | 2025-09-09 | 贝勒医学院 | 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法 |
| WO2022109340A1 (en) * | 2020-11-20 | 2022-05-27 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Immunomodulatory clinical biomarker profiles and uses thereof |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| WO2022153295A1 (en) * | 2021-01-12 | 2022-07-21 | Hadasit Medical Research Services & Development Ltd. | Improved adoptive cell transfer therapy for cancer |
| KR20230148837A (ko) | 2021-02-25 | 2023-10-25 | 라이엘 이뮤노파마, 인크. | Ror1 표적화 키메라 항원 수용체 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB9314623D0 (en) * | 1993-07-14 | 1993-08-25 | Nordion Int Inc | Localization and therapy with agents directed against prostate specific antigen in breast cancer |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6630576B2 (en) | 1998-04-03 | 2003-10-07 | Pennsylvania State Research Foundation | Amino acid substitution mutants of interleukin 13 |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| US20030170238A1 (en) * | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| EP1621551A1 (en) * | 2004-07-27 | 2006-02-01 | Centre National De La Recherche Scientifique | Use of LLT1 and/or CD161 for modulating the activity of cells of the immune system |
| WO2009097119A2 (en) * | 2008-01-29 | 2009-08-06 | Fred Hutchinson Cancer Research Center | Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity |
-
2009
- 2009-01-28 WO PCT/US2009/000554 patent/WO2009097119A2/en not_active Ceased
- 2009-01-28 ES ES09705748.3T patent/ES2666667T3/es active Active
- 2009-01-28 CA CA2713462A patent/CA2713462C/en active Active
- 2009-01-28 EP EP09705748.3A patent/EP2245142B1/en active Active
- 2009-01-28 US US12/865,221 patent/US9090875B2/en active Active
- 2009-01-28 EP EP17209395.7A patent/EP3363893B1/en active Active
- 2009-01-28 JP JP2010545015A patent/JP2011510653A/ja active Pending
- 2009-01-28 ES ES17209395T patent/ES2890729T3/es active Active
-
2014
- 2014-01-31 JP JP2014017760A patent/JP6324092B2/ja active Active
-
2015
- 2015-07-27 US US14/810,286 patent/US9931384B2/en active Active
- 2015-11-12 JP JP2015222014A patent/JP2016027828A/ja active Pending
-
2017
- 2017-09-15 JP JP2017178253A patent/JP6665141B2/ja active Active
-
2018
- 2018-02-23 US US15/903,214 patent/US10653756B2/en active Active
- 2018-12-12 JP JP2018232409A patent/JP2019041772A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014087372A5 (enExample) | ||
| Sivanathan et al. | Interleukin-17A-induced human mesenchymal stem cells are superior modulators of immunological function | |
| Flippe et al. | Future prospects for CD8+ regulatory T cells in immune tolerance | |
| Luque-Campos et al. | Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response | |
| Ahlers et al. | Memories that last forever: strategies for optimizing vaccine T-cell memory | |
| JP2015131795A5 (enExample) | ||
| Butler et al. | Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy | |
| Rettinger et al. | The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells | |
| Dhingra et al. | Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stem cells and restores postinfarction ventricular function | |
| Leong et al. | Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells | |
| Terrén et al. | Implication of interleukin-12/15/18 and ruxolitinib in the phenotype, proliferation, and polyfunctionality of human cytokine-preactivated natural killer cells | |
| Braga et al. | The role of regulatory T cells and TH17 cells in multiple myeloma | |
| MX2022009849A (es) | Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas. | |
| JP2018524987A5 (enExample) | ||
| WO2016011210A3 (en) | Engineered cells for adoptive cell therapy | |
| MY160590A (en) | Cd127 binding proteins | |
| JP2016509840A5 (enExample) | ||
| Nair et al. | The natural killer cell dysfunction of aged mice is due to the bone marrow stroma and is not restored by IL‐15/IL‐15Rα treatment | |
| MX2020001358A (es) | Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso. | |
| RU2017111300A (ru) | Центральные т-клетки памяти для адоптивной т-клеточной терапии | |
| JP5937003B2 (ja) | 免疫介在性疾患における臨床応用のための、抑制機能の高められた制御性ｔ細胞のエクスビボ増加方法 | |
| JP2018522040A5 (enExample) | ||
| Chen et al. | Gene delivery with IFN-γ-expression plasmids enhances the therapeutic effects of MSCs on DSS-induced mouse colitis | |
| JP2013537187A5 (enExample) | ||
| JP2019520823A5 (enExample) |